MYL7 (Myosin Light Chain 7) is a Protein Coding gene. Diseases associated with MYL7 include Fechtner Syndrome and Familial Atrial Fibrillation. Among its related pathways are Activation of cAMP-Dependent PKA and Tight junction. GO annotations related to this gene include calcium ion binding. An important paralog of this gene is MYL5. Myosins are a large family of motor proteins that share the common features of ATP hydrolysis (ATPase enzyme activity), actin binding and potential for kinetic energy transduction. Originally isolated from muscle cells, almost all eukaryotic cells are known to contain myosins.

Human Myosin regulatory light chain 2, atrial isoform (MYL7) ELISA Kit employs a two-site sandwich ELISA to quantitate MYL7 in samples. An antibody specific for MYL7 has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and anyMYL7 present is bound by the immobilized antibody. After removing any unbound substances, a biotin-conjugated antibody specific for MYL7 is added to the wells. After washing, Streptavidin conjugated Horseradish Peroxidase (HRP) is added to the wells. Following a wash to remove any unbound avidin-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of MYL7 bound in the initial step. The color development is stopped and the intensity of the color is measured.

Human Myosin regulatory light chain 2, atrial isoform (MYL7) ELISA Kit listed herein is for research use only and is not intended for use in human or clinical diagnosis. Suggested applications of our products are not recommendations to use our products in violation of any patent or as a license. We cannot be responsible for patent infringements or other violations that may occur with the use of this product.

Find more details at http://www.abbkine.com/product/human-myosin-regulatory-light-chain-2-atrial-isoform-myl7-elisa-kit-kte61438/

Abbkine Scientific Co., Ltd. was founded by a number of scientists and marketing experts in the field of life science in California in 2012. With growing demands from Asia Pacific, it move its headquarters to China. Combining cutting edge technology from United States with China's manufacturing engineering and cost advantages, we aim to provide innovative, high quality assay kits, recombinant proteins, antibodies and other research tools to accelerate life science fundamental research, drug discovery, etc.